International audienceBroadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) are promising molecules for therapeutic or prophylactic interventions. Beyond neutralization, bNAbs exert Fc-dependent functions including antibody-dependent cellular cytotoxicity and activation of the complement. Here, we show that a subset of bNAbs targeting the CD4 binding site and the V1/V2 or V3 loops inhibit viral release from infected cells. We combined immunofluorescence, scanning electron microscopy, transmission electron microscopy and immunogold staining to reveal that some bNAbs form large aggregates of virions at the surface of infected cells. This activity correlates with the capacity of bNAbs to bind to Env at the cel...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Anti-HIV-1 broadly neutralizing antibodies (BnAbs) exhibit an impressive capacity to protect against...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
International audienceBroadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprot...
International audienceThe Fc region of HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) is...
International audienceThe neutralizing activity of anti-HIV-1 antibodies is typically measured in as...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Abstract HIV-1 spreads through contacts between infected and target cells. Polarized viral budding a...
International audienceThe effect of anti-HIV-1 antibodies on complement activation at the surface of...
International audienceBroadly neutralizing antibodies (bNAbs) offer promising opportunities for prev...
An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for HIV-1 vacci...
An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for HIV-1 vacci...
Human immunodeficiency virus type 1 (HIV-1) infection can spread efficiently from infected to uninfe...
Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 in...
International audienceHIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usu...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Anti-HIV-1 broadly neutralizing antibodies (BnAbs) exhibit an impressive capacity to protect against...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
International audienceBroadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprot...
International audienceThe Fc region of HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) is...
International audienceThe neutralizing activity of anti-HIV-1 antibodies is typically measured in as...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Abstract HIV-1 spreads through contacts between infected and target cells. Polarized viral budding a...
International audienceThe effect of anti-HIV-1 antibodies on complement activation at the surface of...
International audienceBroadly neutralizing antibodies (bNAbs) offer promising opportunities for prev...
An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for HIV-1 vacci...
An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for HIV-1 vacci...
Human immunodeficiency virus type 1 (HIV-1) infection can spread efficiently from infected to uninfe...
Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 in...
International audienceHIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usu...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Anti-HIV-1 broadly neutralizing antibodies (BnAbs) exhibit an impressive capacity to protect against...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...